Fast and accurate solution for high-resolution HLA typing using Oxford Nanopore sequencing technology, from sample to result in under 5 hours.

Detailed Description

Nanotype® is a comprehensive solution from Werfen for high-resolution HLA typing based on nanopore sequencing technology (Oxford Nanopore Technologies). Designed to deliver fast, accurate, and complete results, it provides detailed genomic information for 11 HLA loci in a single workflow, from sample to final analysis, in under 5 hours.

Nanotype Workflow

The Nanotype® workflow relies on a long-range PCR strategy covering all relevant HLA genes, followed by optimized library preparation and real-time sequencing. Thanks to the continuous, full-molecule read provided by nanopore technology, the system delivers results with fully assembled haplotypes, eliminating the need for subsequent ambiguous resolution phases.

Data analysis is performed using dedicated software, which provides allele assignment, automatic read validation, and intuitive visualization of the covered regions. Furthermore, it incorporates a clinical variant interpretation tool, facilitating decision-making in histocompatibility and transplant environments.

Nanotype® allows the sequencing of multiple samples in a single workflow, making it ideal for laboratories looking to optimize turnaround time without compromising quality or genetic coverage.

Key Features

High-resolution HLA typing based on Oxford Nanopore technology.
Comprehensive analysis of 11 HLA loci in a single workflow.
Fully assembled haplotypes without ambiguities.
Results in under 5 hours from sample to report.
Clear visualization of covered regions and detected variants.
Compatible with ONT sequencing devices (e.g., GridION).
Integrated data analysis with clinical interpretation.
Scalable for multiple samples.
Nanotype analysis software

Ordering Information

Kit name: Nanotype® Contents: reagents for amplification, library preparation, and bioinformatics analysis Loci coverage: HLA-A, -B, -C, -DRB1, -DRB3, -DRB4, -DRB5, -DQA1, -DQB1, -DPA1, -DPB1 Technology: nanopore sequencing (Oxford Nanopore Technologies) Recommended platform: GridION Total process time: <5 hours (from DNA to result) Software: dedicated module with clinical variant interpretation

Area:

High resolution HLA typing, Immunology, Pre transplantation

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

Franklin by QIAGEN for Somatic Analysis

Advanced cloud-based bioinformatics platform designed for the automated analysis, interpretation, and classification of somatic variants in oncology. Through an integrated environment, the system evaluates clinical evidence in real time, automates classification in accordance with AMP/ASCO/CAP guidelines, and provides access to currently active clinical trials. Detailed description Operating principle End-to-end cloud-based solution for the clinical interpretation…
Qiagen
Next Generation Sequencing (NGS)

SeqOne Genomics – Somatic

SeqOne is a bioinformatics platform for NGS data analysis in precision oncology, designed to detect, prioritise and interpret somatic variants and generate actionable clinical reports from raw sequencing data. It helps laboratories and healthcare professionals accelerate the interpretation of NGS data through an end-to-end workflow. Detailed description Operating principle SeqOne Genomics is a genomic data…
SeqOne
Next Generation Sequencing (NGS)

MSK-ACCESS® powered with SOPHiA DDM™

In-house liquid biopsy solution based on hybrid-capture next-generation sequencing (NGS) technology for the ultrasensitive detection of somatic alterations in circulating cell-free DNA from plasma. Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it implements a robust matched tumor-normal sequencing approach (plasma cfDNA + white blood cell DNA) to filter germline variants and mutations…
SOPHIA Genetics
Next Generation Sequencing (NGS)

MSK-IMPACT® / MSK-IMPACT® FLEX

Decentralised, in-house comprehensive genomic profiling (CGP) solution for solid tumours, based on hybrid capture next-generation sequencing (NGS). Developed in collaboration with Memorial Sloan Kettering Cancer Center (MSK), it features a robust matched tumour-normal sequencing approach for filtering germline variants and clonal haematopoiesis. Detailed description Operating principle The decentralised MSK-IMPACT® powered with SOPHiA DDM™ solution enables…
SOPHIA Genetics
Next Generation Sequencing (NGS)